Health‐related quality of life in reduced‐intensity hematopoietic cell transplantation based on donor availability in patients aged 50–75 with advanced myelodysplastic syndrome: <scp>BMT CTN</scp> 1102-Reference-Cited by-同舟云学术

Health‐related quality of life in reduced‐intensity hematopoietic cell transplantation based on donor availability in patients aged 50–75 with advanced myelodysplastic syndrome: BMT CTN 1102

Published:2022-11-21 Issue:2 Volume:98 Page:229-250
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:American J Hematol

Author:

Cusatis Rachel¹^ORCID,Martens Michael J.¹²^ORCID,Nakamura Ryotaro³,Cutler Corey S.⁴,Saber Wael¹,Lee Stephanie J.¹⁵^ORCID,Logan Brent R.¹²,Shaw Bronwen E.¹,Gregory Alyssa⁶,D'Souza Anita¹^ORCID,Hamilton Betty K.⁷^ORCID,Horowitz Mary M.¹,Flynn Kathryn E.¹^ORCID

Affiliation:

1. CIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine Medical College of Wisconsin Milwaukee Wisconsin USA

2. Division of Biostatistics, Institute for Health and Equity Medical College of Wisconsin Milwaukee Wisconsin USA

3. Department of Hematology & Hematopoietic Cell Transplantation City of Hope Duarte California USA

4. Division of Stem Cell Transplantation and Cellular Therapy Dana‐Farber Cancer Institute Boston Massachusetts USA

5. Fred Hutchinson Cancer Center Seattle Washington USA

6. Emmes Company Rockville Maryland USA

7. Blood & Marrow Transplant Program Cleveland Clinic Taussig Cancer Institute Cleveland Ohio USA

Funder

National Cancer Institute

National Institute of Allergy and Infectious Diseases

Health Resources and Services Administration

Office of Naval Research

Be The Match Foundation

Medical College of Wisconsin

AbbVie

Accenture

Actinium Pharmaceuticals

Adaptive Biotechnologies

Amgen

Astellas Pharma US

bluebird bio

Bristol Myers Squibb Co.

CareDx

CytoSen Therapeutics

Daiichi Sankyo Co., Ltd.

Genentech

Gilead

GlaxoSmithKline

Incyte

Janssen Biotech

Jazz Pharmaceuticals

Karyopharm Therapeutics

Kiadis Pharma

Kyowa Kirin

Medac

Merck

Miltenyi Biotec

MorphoSys

Novartis Pharmaceuticals Corporation

Omeros Corporation

Pfizer

Pharmacyclics

Sanofi Genzyme

Seagen

StemCyte

Takeda Pharmaceuticals U.S.A.

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26768

Reference17 articles.

1. Review of Stem-Cell Transplantation for Myelodysplastic Syndromes in Older Patients in the Context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome Emanating From the Centers for Medicare and Medicaid Services

2. Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome

3. Current Use of and Trends in Hematopoietic Cell Transplantation in the United States

4. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients

5. Approach to anemia associated with myelodysplastic syndromes;Hellström‐Lindberg E;Curr Hematol Rep,2003

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hematopoietic cell transplantation (HCT) in MDS patients of older age;Leukemia & Lymphoma;2024-02-05

2. Cost-Effectiveness of Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Older Patients With High-Risk Myelodysplastic Syndrome: Analysis of BMT CTN 1102;JCO Oncology Practice;2024-01-23

3. Incorporating patient‐reported outcome data into a predictive calculator for allogeneic hematopoietic cell transplantation recipients;Cancer;2024-01-10